Sort   by:  
 Page size 
ProteomicsYBX3 is a versatile RNA-binding protein that controls amino acid import by regulating SLC mRNA abundance
Summary: Amino acids (AA) support protein synthesis, and thus cell growth and proliferation. Specialized transporters mediate AA exchange across membranes and their regulation is critical for AA homeostasis. Here, we report that the DNA- and RNA-binding protein YBX3 regulates the expression of AA t...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2018-11-06 | MSV000083108 | MassIVE
UnknownThe immune-body cytokine network defines a social architecture of cell interactions.
Not available
S-EPMC1636025 | biostudies-literature
TranscriptomicsTranscription profiling of expressed human chromosome 21 genes in transchromosomic mouse embryos carrying a freely segregating copy of Hsa21
Detection of expressed human chromosome 21 genes in transchromosomic mouse embryos carrying a freely segregating copy of Hsa21.
ORGANISM(S): Mus musculus 
2005-11-19 | E-MEXP-409 | biostudies-arrayexpress
UnknownA prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Not available
S-EPMC8576477 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839 | biostudies-literature
UnknownInterim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Not available
S-EPMC6880781 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8941448 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
Sort   by:  
 Page size